Quantamental Technologies LLC bought a new position in Clovis Oncology (NASDAQ:CLVS) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,546 shares of the biopharmaceutical company’s stock, valued at approximately $53,000.
Several other institutional investors and hedge funds have also recently made changes to their positions in CLVS. Comerica Bank acquired a new position in shares of Clovis Oncology in the first quarter worth about $740,000. Gabelli Funds LLC lifted its position in shares of Clovis Oncology by 200.0% in the first quarter. Gabelli Funds LLC now owns 44,700 shares of the biopharmaceutical company’s stock worth $1,109,000 after purchasing an additional 29,800 shares in the last quarter. Spark Investment Management LLC lifted its position in shares of Clovis Oncology by 51.2% in the first quarter. Spark Investment Management LLC now owns 673,100 shares of the biopharmaceutical company’s stock worth $16,706,000 after purchasing an additional 227,800 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in shares of Clovis Oncology in the first quarter worth approximately $192,000. Finally, Pictet Asset Management Ltd. lifted its position in shares of Clovis Oncology by 49.5% in the first quarter. Pictet Asset Management Ltd. now owns 145,800 shares of the biopharmaceutical company’s stock worth $3,619,000 after purchasing an additional 48,300 shares in the last quarter. Institutional investors own 91.69% of the company’s stock.
A number of research firms have recently issued reports on CLVS. BidaskClub lowered shares of Clovis Oncology from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 27th. Goldman Sachs Group lowered shares of Clovis Oncology from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $17.00 to $15.00 in a research report on Wednesday, May 29th. HC Wainwright reissued a “buy” rating on shares of Clovis Oncology in a research report on Wednesday, July 3rd. Barclays set a $36.00 price target on shares of Clovis Oncology and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Royal Bank of Canada set a $26.00 price target on shares of Clovis Oncology and gave the stock a “buy” rating in a research report on Friday, August 2nd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $25.09.
Shares of NASDAQ:CLVS traded up $0.07 during trading on Friday, reaching $5.78. The stock had a trading volume of 58,009 shares, compared to its average volume of 3,114,332. Clovis Oncology has a 52 week low of $4.98 and a 52 week high of $34.63. The firm has a market capitalization of $315.39 million, a price-to-earnings ratio of -0.80 and a beta of 1.91. The company has a quick ratio of 3.32, a current ratio of 3.57 and a debt-to-equity ratio of 8.04. The stock has a fifty day simple moving average of $6.97 and a two-hundred day simple moving average of $16.33.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($2.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.70) by ($0.57). Clovis Oncology had a negative net margin of 332.18% and a negative return on equity of 372.68%. The firm had revenue of $32.98 million during the quarter, compared to the consensus estimate of $34.92 million. During the same period in the prior year, the business earned ($1.94) EPS. The company’s revenue for the quarter was up 38.8% compared to the same quarter last year. On average, analysts forecast that Clovis Oncology will post -7.51 EPS for the current year.
In other news, Director James C. Blair purchased 40,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were bought at an average price of $5.84 per share, with a total value of $233,600.00. Following the completion of the transaction, the director now directly owns 33,439 shares in the company, valued at approximately $195,283.76. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider Patrick J. Mahaffy purchased 50,000 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $5.59 per share, for a total transaction of $279,500.00. Following the transaction, the insider now owns 919,187 shares of the company’s stock, valued at $5,138,255.33. The disclosure for this purchase can be found here. In the last three months, insiders bought 107,800 shares of company stock worth $612,094 and sold 2,597 shares worth $30,139. Company insiders own 8.30% of the company’s stock.
Clovis Oncology Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Further Reading: What is an inverted yield curve?
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.